CONTEXT: Minimal residual disease (MRD) in patients treated for hairy cell (HC) leukemia as assessed by immunohistochemistry has not been included routinely in evaluation of treatment results. OBJECTIVE: To assess the presence of persistent HCs after treatment, as detected by immunohistochemistry, and to evaluate the correlation between the level of MRD and clinical outcome. DESIGN: Percentages of DBA.44-positive HCs were assessed on 116 biopsy specimens from 17 patients. The patients had a median follow-up of 55.4 months. RESULTS: Minimal residual disease was seen in 3 patterns. Group 1 (7 patients) had MRD levels ranging from "rare scattered suspicious HCs" to less than 1%. The MRD levels were stable throughout follow-up, and all patients remained in complete remission. Group 2 (6 patients) had MRD levels ranging from 1% to 5%, and 3 patients were in complete remission at 77.9, 63.8, and 108.0 months. Another patient showed evidence of disease activity (partial remission) at 47.6 months. Two other patients relapsed at 12.3 months and at 25.7 months, respectively, with greater than 1% HCs. Group 3 (4 patients) had MRD levels greater than 5%. Three patients relapsed at 11.3, 12.1, and 29.6 months, respectively, with greater than 5% HCs. The fourth patient had MRD levels of 5% at 14.6 months and 2% at 20.0 months but was subsequently lost to follow-up. CONCLUSIONS: Quantitative assessment of MRD may be of value in identifying patients at risk for relapse of hairy cell leukemia.
CONTEXT: Minimal residual disease (MRD) in patients treated for hairy cell (HC) leukemia as assessed by immunohistochemistry has not been included routinely in evaluation of treatment results. OBJECTIVE: To assess the presence of persistent HCs after treatment, as detected by immunohistochemistry, and to evaluate the correlation between the level of MRD and clinical outcome. DESIGN: Percentages of DBA.44-positive HCs were assessed on 116 biopsy specimens from 17 patients. The patients had a median follow-up of 55.4 months. RESULTS: Minimal residual disease was seen in 3 patterns. Group 1 (7 patients) had MRD levels ranging from "rare scattered suspicious HCs" to less than 1%. The MRD levels were stable throughout follow-up, and all patients remained in complete remission. Group 2 (6 patients) had MRD levels ranging from 1% to 5%, and 3 patients were in complete remission at 77.9, 63.8, and 108.0 months. Another patient showed evidence of disease activity (partial remission) at 47.6 months. Two other patients relapsed at 12.3 months and at 25.7 months, respectively, with greater than 1% HCs. Group 3 (4 patients) had MRD levels greater than 5%. Three patients relapsed at 11.3, 12.1, and 29.6 months, respectively, with greater than 5% HCs. The fourth patient had MRD levels of 5% at 14.6 months and 2% at 20.0 months but was subsequently lost to follow-up. CONCLUSIONS: Quantitative assessment of MRD may be of value in identifying patients at risk for relapse of hairy cell leukemia.
Authors: Michael R Grever; Omar Abdel-Wahab; Leslie A Andritsos; Versha Banerji; Jacqueline Barrientos; James S Blachly; Timothy G Call; Daniel Catovsky; Claire Dearden; Judit Demeter; Monica Else; Francesco Forconi; Alessandro Gozzetti; Anthony D Ho; James B Johnston; Jeffrey Jones; Gunnar Juliusson; Eric Kraut; Robert J Kreitman; Loree Larratt; Francesco Lauria; Gerard Lozanski; Emili Montserrat; Sameer A Parikh; Jae H Park; Aaron Polliack; Graeme R Quest; Kanti R Rai; Farhad Ravandi; Tadeusz Robak; Alan Saven; John F Seymour; Tamar Tadmor; Martin S Tallman; Constantine Tam; Enrico Tiacci; Xavier Troussard; Clive S Zent; Thorsten Zenz; Pier Luigi Zinzani; Brunangelo Falini Journal: Blood Date: 2016-11-30 Impact factor: 22.113
Authors: Robert J Kreitman; Wyndham Wilson; Katherine R Calvo; Evgeny Arons; Laura Roth; Jeffrey Sapolsky; Hong Zhou; Mark Raffeld; Maryalice Stetler-Stevenson Journal: Clin Cancer Res Date: 2013-11-25 Impact factor: 12.531